Proteomics International Laboratories (ASX:PIQ) secures Hong Kong patent for PromarkerD

• Proteomics International Laboratories (PIQ) secures a patent in Hong Kong for its diabetic kidney test, PromarkerD
• The patent is titled ‘Biomarkers associated with pre-diabetes, diabetes and diabetes related conditions’ and is valid until September 2031
• It complements those already received in the US, Australia, Japan, China and Canada
• PromarkerD is a simple, low-cost blood test that uses a unique protein ‘fingerprint’ to detect the onset of diabetic kidney disease up to four years before symptoms appear
• Proteomics is up 2.27 per cent with shares trading at 90 cents at 3:06 pm AEDT

Proteomics International Laboratories (PIQ) has secured a patent in Hong Kong for its diabetic kidney test, PromarkerD.

The patent is titled ‘Biomarkers associated with pre-diabetes, diabetes and diabetes related conditions’ and is valid until September 2031.

This patent complements those already received in the US, Australia, China, Japan, Singapore, Indonesia, Brazil, Canada, Russia, Europe and India.

Managing Director Dr Richard Lipscombe said securing a patent in Hong Kong complements its patent protection in the region.

“Proteomics International already has patent protection in China and the granting of the Hong Kong patent, which includes pre-diabetes. expands that protection,” he said.

“Hong Kong is an important gateway market and there is the potential for PromarkerD testing to be introduced there prior to entering the much larger China market.”

PromarkerD is a simple, low-cost blood test that uses a unique protein ‘fingerprint’ to detect the onset of diabetic kidney disease up to four years before symptoms appear.

It allows patients to apply preventative measures before kidney damage occurs, leading to better outcomes for the patient and simplified care for physicians.

Proteomics was up 2.27 per cent with shares trading at 90 cents at 3:06 pm AEDT.